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Background: The introduction of the Sensititre® MYCOTB MIC
plate a microtitre plate containing lyophilized antibiotics and con-
ﬁgured for thedeterminationofminimuminhibitory concentration
to ﬁrst and second line anti-tuberculosis drugs can change the
laborious methods currently used for drug susceptibility testing.
At present reputable procedures for susceptibility testing of M.
tuberculosis categorize clinical isolates as either drug resistant
or drug susceptible due to their ability to grow in the presence
of mostly single critical concentration despite of whether high
level, moderate level or low level drug resistance is present. The
limited scientiﬁc background for critical concentrations used for
particularly second-line drugs is especially problematic. The deter-
mination ofM. tuberculosis susceptibility testing usingMICs instead
of useof critical concentrationwill be oneof theﬁrst in SouthAfrica.
However, the performance of the Sensititre plate has not been com-
pared to methods that uses MICs for susceptibility testing the agar
proportion method and Etest.
Objective: To evaluate Sensititre® MYCOTB MIC plate perfor-
mance against agar proportion (APM) and Etest methods
Methods&Materials: Seventy-ﬁveM. tuberculosis isolateswere
included in the study. Isolates were collected from the Drug Resis-
tance survey currently being carried out in South Africa since
2012. The full spectrum of resistance from mono-resistance and
poly-resistance through MDRTB, to pre-XDRTB and XDRTB.were
included in the study. MICs categorical and essential agreements
(± 1dilution from critical concentration) were compared of the
microtitre Sensititre MYCOTB plate method against the agar pro-
portion and the Etest methods.
Results: Essential agreement between Sensititre plate and APM
with respect to susceptible or resistant was 92% for 10 of 11 drugs
and 96% by categorical agreement. For ethambutol, essential agree-
ment was 80-81%. while for moxiﬂoxacin, agreement was 83-85%.
Categorical agreement between Etest and APM methods was 100%
for rifampin, ethambutol, streptomycin, and oﬂoxacin and 98% for
isoniazid. They was a high rate of contamination with Etest which
warranted many repeats. For MYCOTB and Etest, median time to
plate interpretation was 10 days while APM it was 21 days.
Conclusion: The Sensititre method provides a more rapid,
quantitative, and efﬁcient method with no test failures due to con-
tamination for both ﬁrst- and second-line drugswhen compared to
the APM and Etest.
http://dx.doi.org/10.1016/j.ijid.2014.03.546
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improve outcomes
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Secondary bacterial infections account for a signiﬁcant portion
of excess mortality during seasonal inﬂuenza epidemics. With the
emergence of the H1N1 pandemic strain in 2009 and the ongoing
threat of a new pandemic from highly pathogenic avian H5N1 or
H7N9 strains, prevention and treatment of bacterial complications
has become an important issue for public health planning. Sev-
eral mechanisms underlie the ability of inﬂuenza viruses to prime
the host for secondary bacterial infections. An improved under-
standing of thesemechanisms has allowed development of speciﬁc
therapies. Prevention by vaccination against either the virus or the
super-infecting bacteria is the ﬁrst line of defense. However, vac-
cines are imperfect and may not be available for pandemic strains.
Treatment of the viral infection using a neuraminidase inhibitor
has been shown to both decrease the incidence of secondary
infection and ameliorate the severity of the resulting pneumonia
from secondary bacterial pathogens. The use of protein synthe-
sis inhibitors rather than cell-wall active antibiotics may be the
preferred therapy in the setting of prior inﬂuenza to reduce the
inﬂammatory burst that occurs during bacterial lysis. Modulation
of this immune response with targeted anti-inﬂammatory thera-
pies may also improve outcomes. The basis for these strategies and
a discussion of their potential application to treatment of bacte-
rial infections complicating inﬂuenza will be discussed during the
seminar.
http://dx.doi.org/10.1016/j.ijid.2014.03.547
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Impact of acellular and whole cell pertussis
vaccines on disease burden
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Since the late 1940s, pertussis vaccines prepared by forma-
lin inactivation of “whole cell” Bordetella pertussis organisms have
resulted in a marked decline in the rates of pertussis disease.
However, concern for local and systemic reactions resulted in the
identiﬁcation and puriﬁcation of several proteins produced by the
Bordetella pertussis organism. New “acellular vaccines,” formulated
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by combining several of these proteins were found to be associ-
ated with fewer reactions and were efﬁcacious. Acellular vaccines
soon replaced whole cell vaccines in many countries, but because
of reduced cost and proven efﬁcacy, whole cell vaccines are still
used inmost developing countries. Therehas been a recent increase
in reported pertussis cases observed in many countries using the
acellular vaccines, especially in young adolescents between 7 to 14
years of age. The reasons for this increase are complex and mul-
tifactorial and include greater intensity of surveillance, improved
method to diagnose pertussis, changes in the biologic charac-
teristics of the Bordetella pertussis organisms, and the types and
schedules of pertussis vaccines used for routine vaccination. Cur-
rent acellular vaccines have been shown to be efﬁcacious in the
short term, but in actual use are failing to be effective in controlling
pertussis in the long term. Recent data suggest that the acellu-
lar vaccines are associated with more rapid waning of immunity,
and that priming with whole cell pertussis vaccine is more effec-
tive than acellular vaccine in preventing disease. There is a clear
need to better understand the differences in the immune responses
induced by acellular and whole cell vaccines after both the pri-
mary and booster series. Nonhuman primate models are shedding
light on the differences in the prevention of disease and transmis-
sion with acellular and whole cell vaccines and on the differences
in immune responses to both vaccine types. Strategies to improve
the current acellular vaccines include; reintroduction of whole cell
vaccines into the vaccine series, the addition of new antigens to
the currently available acellular vaccines, the use of adjuvants to
enhance speciﬁc immune responses, and the utility of a new live
attenuated intranasal pertussis vaccine
http://dx.doi.org/10.1016/j.ijid.2014.03.548
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Dengue vaccine development: An update
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Recent estimates on the burden of DENV infection deter-
mined that there are 390 million dengue infections per year,
three times the current estimate by the WHO. Since vector
control programs have been largely unsuccessful in preventing
outbreaks, vaccination seems to be the most viable option for
prevention. The development of dengue vaccines has been ham-
pered by the theoretical risk of vaccine-related adverse events
such as immune enhancement, and the requirement to induce a
long-lasting protective immune response against all four dengue
serotypes simultaneously. Other challenges include the lack of an
adequate animal model of disease, absence of an immune corre-
late of protection, and only partially informative immunogenicity
assays. Currently, several kinds of dengue vaccines are in develop-
ment, but only one of these candidates (a chimeric dengue-yellow
fever live attenuated vaccine) has reached the stage of phase 3 clin-
ical trials. Live dengue vaccine candidates have been administered
to ten thousands of volunteers and were well-tolerated, with mini-
mal short-termsafetyeffects reported inPhase I andPhase II clinical
trials. Based on the natural history of dengue, a theoretical possi-
bility of an increased risk of severe dengue as a consequence of
vaccination has been hypothesized but not yet observed. Despite
good safety and immunogenicity proﬁles registered, issues such as
imbalanced immune responses between serotypes and lack of clin-
ical protective efﬁcacy in the ﬁrst results of Phase 3 trials have been
a major set-back in the development of an urgently needed dengue
vaccine.
http://dx.doi.org/10.1016/j.ijid.2014.03.549
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Endgame polio - Vaccine strategies to achieve
an end
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As of December 18, 360 cases of wild type 1 poliomyelitis
and 58 cases of paralysis caused by circulating vaccine-derived
polioviruses (cVDPV) were reported to WHO in 2013 compared
with 223 wild type and 70 cVDPV in calendar year 2012. No wild
type 3 cased occurred and all cVDPV cases were attributed to type
2 Sabin derived strains. Among the 3 endemic countries, Nigeria
and Afghanistan made substantive progress in controlling WPV1
disease with year-over-year reductions of 58% and 68%, respec-
tively, and further localization of areas experiencing endemic cases.
In contrast, Pakistan recorded 75 new cases, an increase of 34%
over 2012 due to outbreaks in areas affected by insecurity and
poor access to unvaccinated children. New WPV1 outbreaks in the
Horn of Africa (203 cases) and Syria (17 cases) were attributed to
export of WPV1 viruses from Nigeria and Pakistan, respectively,
and 4 cases of paralysis occurred in Cameroon, caused by a WPV1
strain that had been circulating undetected for an estimated 2-3
years.WPV1viruses related to the Syrianoutbreakweredetected in
environmental surveillance samples beginning in May, 2013 with-
out evidence of paralytic disease in this highly vaccinated country.
In response, the Israeli Ministry of Health has re-introduced OPV
into the national immunization schedule.
Insecurity, threats to polio vaccination teams, and gaps in sup-
plemental immunization activity (SIA) campaign quality are now
major obstacles to eradication which are being addressed by the
GPEI in multiple ways including engagement of government and
religious leaders and other relevant third parties, and introduction
of methods to assess and improve SIA coverage. Ongoing recovery
of cVDPV viruses from children with acute ﬂaccid paralysis (AFP)
and from environmental surveillance specimens in under immu-
nized areas will mean that cessation of all OPV immunization will
need to cease in a globally coordinated manner. The 2013-2018
GPEI Strategic Plan calls for complete control of all wild poliovirus
transmission the end of 2014, introduction of one or more IPV
doses for routine immunization by Q3 2015 for risk mitigation, and
replacement of all trivalent OPV with bivalent type 1 and 3 OPV
in Q2 2016. With global certiﬁcation of eradication by the end of
2018, all OPV vaccines will be discontinued and replaced by IPV.
New tools to assist in achieving and maintaining eradication
areunderdevelopment includingnew, affordable IPV formulations,
genetically stable OPV vaccines derived from current Sabin strains,
